Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Current Deferred Revenue data on file, last reported at $13.3 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 51.41% year-over-year to $13.3 million in Q2 2026; TTM through May 2026 was $13.3 million, a 51.41% decrease from a year earlier, with the FY2025 full-year figure at $17.6 million, down 54.18% from the prior year.
• Current Deferred Revenue for Q2 2026 stood at $13.3 million, down from $18.8 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for NRIX reached as high as $48.1 million in Q4 2023 and fell as low as $13.3 million in Q2 2026.
• Historically, Current Deferred Revenue has averaged $35.2 million across 5 years, with a median of $38.0 million in 2022.
• Across the five-year window, Current Deferred Revenue soared 49.82% in 2024 and slumped 54.18% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $37.6 million in 2022, then increased by 27.81% to $48.1 million in 2023, then decreased by 20.24% to $38.4 million in 2024, then slumped by 54.18% to $17.6 million in 2025, then retreated by 24.21% to $13.3 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $13.3 million in Q2 2026, $18.8 million in Q1 2026, and $17.6 million in Q4 2025.